166 related articles for article (PubMed ID: 30582964)
21. Design of FK866-Based Degraders for Blocking the Nonenzymatic Functions of Nicotinamide Phosphoribosyltransferase.
Lu T; Chen F; Yao J; Bu Z; Kyani A; Liang B; Chen S; Zheng Y; Liang H; Neamati N; Liu Y
J Med Chem; 2024 May; 67(10):8099-8121. PubMed ID: 38722799
[TBL] [Abstract][Full Text] [Related]
22. Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway.
Feng J; Yan PF; Zhao HY; Zhang FC; Zhao WH; Feng M
Biomed Res Int; 2016; 2016():1450843. PubMed ID: 28097126
[TBL] [Abstract][Full Text] [Related]
23. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
Sociali G; Raffaghello L; Magnone M; Zamporlini F; Emionite L; Sturla L; Bianchi G; Vigliarolo T; Nahimana A; Nencioni A; Raffaelli N; Bruzzone S
Oncotarget; 2016 Jan; 7(3):2968-84. PubMed ID: 26658104
[TBL] [Abstract][Full Text] [Related]
24. Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells.
Travelli C; Drago V; Maldi E; Kaludercic N; Galli U; Boldorini R; Di Lisa F; Tron GC; Canonico PL; Genazzani AA
J Pharmacol Exp Ther; 2011 Sep; 338(3):829-40. PubMed ID: 21685314
[TBL] [Abstract][Full Text] [Related]
25. Targeting the NAD
Ye C; Qi L; Li X; Wang J; Yu J; Zhou B; Guo C; Chen J; Zheng S
Cell Commun Signal; 2020 Jan; 18(1):16. PubMed ID: 32005247
[TBL] [Abstract][Full Text] [Related]
26. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
Okumura S; Sasaki T; Minami Y; Ohsaki Y
J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
[TBL] [Abstract][Full Text] [Related]
27. High expression of NAMPT in adult T-cell leukemia/lymphoma and anti-tumor activity of a NAMPT inhibitor.
Kozako T; Aikawa A; Ohsugi T; Uchida YI; Kato N; Sato K; Ishitsuka K; Yoshimitsu M; Honda SI
Eur J Pharmacol; 2019 Dec; 865():172738. PubMed ID: 31614144
[TBL] [Abstract][Full Text] [Related]
28. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
Hasmann M; Schemainda I
Cancer Res; 2003 Nov; 63(21):7436-42. PubMed ID: 14612543
[TBL] [Abstract][Full Text] [Related]
29. EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.
Zucal C; D'Agostino VG; Casini A; Mantelli B; Thongon N; Soncini D; Caffa I; Cea M; Ballestrero A; Quattrone A; Indraccolo S; Nencioni A; Provenzani A
BMC Cancer; 2015 Nov; 15():855. PubMed ID: 26542945
[TBL] [Abstract][Full Text] [Related]
30. Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice.
Nencioni A; da Silva RF; Fraga-Silva RA; Steffens S; Fabre M; Bauer I; Caffa I; Magnone M; Sociali G; Quercioli A; Pelli G; Lenglet S; Galan K; Burger F; Vázquez Calvo S; Bertolotto M; Bruzzone S; Ballestrero A; Patrone F; Dallegri F; Santos RA; Stergiopulos N; Mach F; Vuilleumier N; Montecucco F
Thromb Haemost; 2014 Feb; 111(2):308-22. PubMed ID: 24196571
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells.
Thakur BK; Dittrich T; Chandra P; Becker A; Lippka Y; Selvakumar D; Klusmann JH; Reinhardt D; Welte K
Biochem Biophys Res Commun; 2012 Aug; 424(3):371-7. PubMed ID: 22728882
[TBL] [Abstract][Full Text] [Related]
32. Oleate ameliorates palmitate-induced reduction of NAMPT activity and NAD levels in primary human hepatocytes and hepatocarcinoma cells.
Penke M; Schuster S; Gorski T; Gebhardt R; Kiess W; Garten A
Lipids Health Dis; 2017 Oct; 16(1):191. PubMed ID: 28974242
[TBL] [Abstract][Full Text] [Related]
33. Targeting of nicotinamide phosphoribosyltransferase enzymatic activity ameliorates lung damage induced by ischemia/reperfusion in rats.
Wu GC; Liao WI; Wu SY; Pao HP; Tang SE; Li MH; Huang KL; Chu SJ
Respir Res; 2017 Apr; 18(1):71. PubMed ID: 28438162
[TBL] [Abstract][Full Text] [Related]
34. Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells.
Thakur BK; Dittrich T; Chandra P; Becker A; Kuehnau W; Klusmann JH; Reinhardt D; Welte K
Int J Cancer; 2013 Feb; 132(4):766-74. PubMed ID: 22815158
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
Tan B; Young DA; Lu ZH; Wang T; Meier TI; Shepard RL; Roth K; Zhai Y; Huss K; Kuo MS; Gillig J; Parthasarathy S; Burkholder TP; Smith MC; Geeganage S; Zhao G
J Biol Chem; 2013 Feb; 288(5):3500-11. PubMed ID: 23239881
[TBL] [Abstract][Full Text] [Related]
36. Fragment-based discovery of a potent NAMPT inhibitor.
Korepanova A; Longenecker KL; Pratt SD; Panchal SC; Clark RF; Lake M; Gopalakrishnan SM; Raich D; Sun C; Petros AM
Bioorg Med Chem Lett; 2018 Feb; 28(3):437-440. PubMed ID: 29287958
[TBL] [Abstract][Full Text] [Related]
37. Optical Redox Imaging of Treatment Responses to Nampt Inhibition and Combination Therapy in Triple-Negative Breast Cancer Cells.
Podsednik A; Jiang J; Jacob A; Li LZ; Xu HN
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070254
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of NAMPT decreases cell growth and enhances susceptibility to oxidative stress.
Xu R; Yuan Z; Yang L; Li L; Li D; Lv C
Oncol Rep; 2017 Sep; 38(3):1767-1773. PubMed ID: 28714034
[TBL] [Abstract][Full Text] [Related]
39. Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes.
Pittelli M; Cavone L; Lapucci A; Oteri C; Felici R; Niccolai E; Amedei A; Chiarugi A
Immunol Cell Biol; 2014 Feb; 92(2):191-9. PubMed ID: 24275857
[TBL] [Abstract][Full Text] [Related]
40. Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity.
Gerner RR; Macheiner S; Reider S; Siegmund K; Grabherr F; Mayr L; Texler B; Moser P; Effenberger M; Schwaighofer H; Moschen AR; Kircher B; Oberacher H; Zeiser R; Tilg H; Nachbaur D
Leukemia; 2020 Jul; 34(7):1885-1897. PubMed ID: 31974433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
